Abstract
4-Carboxy-α-[3-(hydroxyamino)-3-oxopropyl]-benzenepropanoic acid 1 is a potent hydroxamatebased inhibitor of glutamate carboxypeptidase II. In an attempt to improve its poor oral pharmacokinetics, we synthesized a series of prodrugs by masking its hydrophilic hydroxamate group. Prodrugs were evaluated for oral availability in mice and showed varying degree of plasma exposure to 1. Of these, para-acetoxybenzyl-based, 4-(5-(((4-acetoxybenzyl)oxy)amino)-2-carboxy-5-oxopentyl)benzoic acid, 12, provided 5-fold higher plasma levels of 1 compared to oral administration of 1 itself. Subsequently, para-acetoxybenzyl-based prodrugs with additional ester promoiety(ies) on carboxylate(s) were examined for their ability to deliver 1 to plasma. Isopropyloxycarbonyloxymethyl (POC) ester 30 was the only prodrug that achieved substantial plasma levels of 1. In vitro metabolite identification studies confirmed stability of the ethyl ester of benzoate while the POC group was rapidly hydrolyzed. At oral daily dose-equivalent of 3 mg/kg, 12 exhibited analgesic efficacy comparable to dose of 10 mg/kg of 1 in the rat chronic constrictive injury model of neuropathic pain.
INTRODUCTION
In the nervous system, a membrane-bound metalloprotease termed glutamate carboxypeptidase II (GCPII) catalyzes the hydrolysis of the abundant neuropeptide Nacetylaspartylglutamate (NAAG), generating glutamate, a major excitatory neurotransmitter, in the extracellular compartment. 1 Inhibition of GCPII has been extensively explored as a therapeutic approach to treatment of neurological disorders associated with glutamate excitotoxicity. To date, a wide variety of small molecule GCPII inhibitors have been identified 2 and many have shown in vivo efficacy in preclinical models of neurological disorders including neuropathic pain. [3] [4] [5] Nearly all potent GCPII inhibitors possess a zincbinding group, such as phosphonate, 6 phosphinate, 7 urea, 8 thiol, 9 and hydroxamate, 10 that interacts with the catalytic zinc atom(s) in the enzyme's active site. Among them, the hydroxamate-based inhibitors represented by 1 ( Figure 1 ) exhibit an unprecedented mode of binding, in which its two carboxylate groups occupy the nonprime side of the carboxypeptidase while the glutamate-binding S1′ pocket remains unoccupied. 10 In addition, despite its high polarity, compound 1 exhibited good distribution to sciatic nerves, 10 which is believed to be the site of action for GCPII inhibitors for attenuating neuropathic pain. 4, 11 Compound 1, however, suffers from poor oral bioavailability, limiting its therapeutic utility as a treatment for chronic pain. We encountered a similar challenge with 2-phosphonomethyl pentanedioic acid (2-PMPA), 6 a potent GCPII inhibitor with negligible oral availability due to its highly polar molecular characteristics. Recently, we reported that oral administration of tris-isopropyloxycarbonyloxymethyl (POC) ester derivative of 2-PMPA resulted in nearly 20-fold enhancement in the plasma exposure of 2-PMPA in mice compared to oral administration of 2-PMPA itself. 12 This approach represents the first successful demonstration of an orally active GCPII prodrug. We hypothesized that this strategy could be extended to other GCPII inhibitors of high polarity.
To this end, we have explored a series of prodrugs of 1, in which the hydroxamate and/or carboxylate group(s) was (were) masked to form more lipophilic species in an attempt to improve oral absorption. Here we present the design, synthesis, and pharmacological evaluation of prodrugs derived from 1 ( Figure 1 ). In addition to acetyl derivative, we introduced O-4-acetoxy benzyl (PAB) and 2-oxo-1,3-dioxol-4-yl methyl (ODOL) groups for the first time as promoieties for hydroxamate-based drugs. The prodrug with the most desirable pharmacokinetics properties was evaluated in an animal model of neuropathic pain following oral administration to assess its in vivo efficacy.
RESULTS

Chemistry
In all of the prodrugs reported herein, a promoiety was incorporated into the hydroxamate group of 1. This is based on our previous findings from thiol-based GCPII inhibitors, which have been shown to exhibit good oral bioavailability despite the presence of two carboxylate groups. 13 We also explored prodrugs in which carboxylate group(s) of 1 were modified in addition to the hydroxamate group in order to assess the effects of the added promoiety(ies) on the oral pharmacokinetic profile.
Synthesis of three prodrugs of 1 bearing a single promoiety at its hydroxamate group is illustrated in Scheme 1. Dicarboxylate 2 was converted to the corresponding di-t-butyl ester 3. The terminal olefin of 3 was oxidized to a carboxylate group, providing compound 4. Coupling with hydroxylamine followed by acetylation and subsequent ester hydrolysis afforded acetylated prodrug 7. A similar approach but involving coupling of 4 with 4-((aminooxy)methyl)phenyl acetate 10 or 4-((aminooxy)methyl)-5-methyl-1,3-dioxol-2-one 15 provided PAB and ODOL-based prodrugs 12 and 17, respectively. Scheme 2 illustrates the synthesis of prodrugs 23, 25, and 30 containing multiple promoieties. Prodrug 23 was synthesized by first converting dicarboxylate 2 into the diethyl ester 18. Two-step conversion of the aliphatic carboxylate ethyl ester into t-butyl ester 20 followed by oxidation of the terminal olefin afforded 21. Coupling of 21 to 10 and subsequent hydrolysis of the t-butyl ester afforded the desired prodrug 23. We also synthesized triple-promoiety prodrug 25 by oxidizing diethyl ester 18 followed by coupling with 10. Preparation of prodrug 30 bearing a benzoate isopropyloxycarbonylmethyl (POC) was initiated by conversion of dicarboxylate 2 into mono-POC ester 26. The selective incorporation of the POC group into the benzoate moiety of 26 was confirmed by 1 H-13 C HMBC spectrum (Supporting Information). The methylene protons (5.99 ppm) of the POC group showed three-bond coupling with the carbonate carbonyl (153.4 ppm) of the POC group and another carbonyl peak at 164.9 ppm. This peak (164.9 ppm) was assigned to the benzoate carbonyl because of its three-bond coupling with the aromatic protons at 8.01 ppm. Compound 26 was subsequently condensed with 2-(trimethylsilyl)ethan-1-ol to give diester 27. Oxidation of 27 into 28 followed by coupling with 10 and selective hydrolysis of trimethylsilylethyl ester by TFA afforded the desired product 30.
GCPII Activity of Prodrugs
Compound 1 and its six prodrugs 7, 12, 17, 23, 25, and 30 were tested for their inhibition potency against GCPII. While 1 exhibited nM potency as previously described (IC 50 = 44 nM), 14 prodrugs 7, 12, 23, 25, and 30 had IC 50 values >5 μM (Figure 2 ). Considering structural data on the compound 1/GCPII complex reported previously, 14 the lack of inhibitory potency of the prodrugs is likely due to the inability of the modified hydroxamate function to chelate active-site zinc ions. The only exception was 17, which exhibited GCPII inhibition, albeit with 12-fold less potency compared to 1 (IC 50 = 540 nM; Figure 2 ). Subsequent stability testing of 17 under identical GCPII enzyme assay conditions (30 m in aqueous buffer; pH 8.0), however, revealed partial hydrolysis to 1, likely accounting for its GCPII inhibitory activity.
Drug Metabolism and Pharmacokinetics
The six prodrugs 7, 12, 17, 23, 25, and 30 were given to mice orally at a dose equivalent of 10 mg/kg of compound 1, and plasma levels of 1 were measured 30 min after the administration (Figure 2 ). For comparison, compound 1 was also administered orally at 10 mg/kg to assess the ability of the prodrugs to achieve enhanced plasma levels of 1. Plasma levels of 1 following oral administration of the prodrugs containing a single promoiety at the hydroxamate group such as 7, 12, and 17 were found to be equal or higher than those following oral administration of compound 1 itself. Compound 12 masked with a paraacetoxybenzyl moiety at the hydroxamate group was a particularly effective prodrug, displaying 5-fold increase in plasma exposure to compound 1. Oral administration of paraacetoxybenzyl-based prodrugs with additional ester promoiety-(ies) 23 and 25, however, resulted in negligible plasma levels of 1. In contrast, para-acetoxybenzyl-based prodrug 30 with a benzoate isopropyloxycarbonyloxymethyl (POC) ester achieved 4-fold increase in plasma levels of 1 as compared to those of oral administration of compound 1 itself.
To understand the structure-activity relationship in terms of bioconversion of prodrugs into compound 1, we assessed metabolism of prodrugs 12, 23, and 30 in plasma ( Figure 1A ). Because compound 1 ( Figure 3B ) was found to be completely stable in mouse plasma ( Figure 3C ), we assumed that the plasma samples treated with a prodrug contain the remaining prodrug, partially hydrolyzed intermediate(s), and/or compound 1. Figure 3D shows an extracted-ion (428.142 for 12) chromatogram of 12 as reference. An extracted mass (280.080 for 1 and 428.080 for 12) chromatogram of plasma sample treated with 12 for 60 min ( Figure 3E ) lost the peak corresponding to 12 and displayed a new peak corresponding to 1, suggesting complete conversion of prodrug 12 to 1 in plasma. In contrast, prodrug 23 ( Figure 3F ) was not converted into 1 in plasma despite the complete loss of 23 after 60 min incubation. An extracted mass (280.080 for 1, 308.120 for 31, and 428.080 for 12) chromatogram shows a new peak matching the mass of 31, ethyl ester of 1 ( Figure 3G ). The results suggest that only para-acetoxybenzyl moiety was removed from 23 in plasma. This explains the negligible plasma levels of 1 following oral administration of 23 ( Figure 2 ). Although speculative, this could be partially attributable to the inability of plasma-rich hydrolases to recognize benzoate esters as a substrate. The inability to hydrolyze the benzoate ester likely prevented formation of 12 from 23 as well. This is apparent as formation of 12 would be immediately followed by the generation of 1 as is evident from the plasma stability data of 12 ( Figure 3D ). Interestingly, prodrug 30 ( Figure  3H ) containing a POC ester was completely hydrolyzed in plasma along with its paraacetoxybenzyl moiety to produce 1 as a sole metabolite as shown in an extracted mass (280.090 for 1 and 428.142 for 30) chromatogram ( Figure 3I ) of plasma treated with prodrug 30. This can be attributed to the ability of hydrolases to act on the carbonate portion of the POC ester away from the benzoate carbonyl moiety. 15 This is in a good agreement with the enhanced plasma levels of 1 following oral administration of 30 as compared to 23 (Figure 2 ).
Chronic Constrictive Injury Model of Neuropathic Pain
On the basis of the highest exposure to compound 1 achieved by oral administration, prodrug 12 was subsequently tested for its antinociceptive effects following oral administration using the rat chronic constriction injury model of neuropathic pain. 16 We have previously shown analgesic effects of compound 1 in the same model following 10 mg/kg/day oral dosing. Given the improved plasma exposure achieved by oral administration of 12, we chose to test 12 at 4.6 mg/kg, an equivalent of 3 mg/kg of compound 1. Gabapentin (50 and 100 mg/kg po daily) was used as a positive control. Hyperalgesia testing was initiated 10 days postsurgery by determining withdrawal latencies in response to a constant thermal stimulus. As shown in Figure 4A , prodrug 12 significantly reduced thermal hyperalgesia relative to the vehicle-treated control on days 4 and 8. In contrast, as shown in Figure 4B , prodrug 12 had no significant effect on absolute latency of the sham operated side, suggesting a selective antihyperalgesic effect on the injured nerve. Similarly, gabapentin (100 mg/kg po) significantly reversed allodynia that was maintained throughout the dosing period (Supporting Information, Figure S4 ).
When compared directly to 1, despite the higher doses (10 mg/kg/day), oral administration of 1 itself first displayed significantly reduced thermal hyperalgesia on day 8 10 as opposed to day 4 for the lower dose of 12. These findings clearly demonstrate the pharmacological advantages of prodrug 12 over the parent compound 1, presumably due to the improved oral pharmacokinetics of 1 achieved by prodrug 12.
CONCLUSIONS
The concept of hydroxamate prodrugs has been only recently reported in the literature, including carbamates, 17, 18 O-acyl derivatives, 19 and 1,4,2-dioxazol-5-one. 20 However, little has been investigated on the oral pharmacokinetics of these prodrugs to assess their pharmacological advantages over the parent compounds. In our work, systematic assessment of prodrugs derived from hydroxamate-based GCPII inhibitor 1 provided key insights into the design strategy for creating an improved oral pharmacokinetic profile. As far as the hydroxamate group is concerned, incorporation of a para-acetoxybenzyl group as represented by prodrug 12 resulted in substantial improvement in pharmacokinetics of 1 as compared to acetyl and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl groups. Prodrugs 23 and 25 containing additional pro-moiety(ies), however, failed to deliver 1 in plasma following oral administration. The inability of 23 and 25 to generate 1 in plasma can be attributed to the resistance of the benzoate ethyl ester to enzymatic hydrolysis reaction. Indeed, paraacetoxybenzyl-based prodrug 30 containing a POC ester was able to release 1 in plasma, presumably because of its carbonate site prone to enzymatic hydrolysis reaction. Consistent with the improved oral pharmacokinetics demonstrated by prodrug 12, at oral daily doses equivalent to 3 mg/kg of 1, prodrug 12 exhibited analgesic efficacy superior to that of oral daily doses of 10 mg/kg of 1 10 and similar to standard of care gabapentin in the rat chronic constrictive injury model (CCI) of neuropathic pain. These findings collectively suggest that the prodrug approach is an effective strategy for improving oral activity of hydroxamatebased GCPII inhibitors. To the best of our knowledge, compound 12 represents the first example of hydroxamate-derived prodrugs with improved in vivo oral pharmacokinetics. This approach has potential application to other hydroxamate-based drugs such as HDAC and MMP inhibitors.
EXPERIMENTAL SECTION General
The commercially available HPLC grade methanol, catalysts, and reagent grade materials were used without further purification. TLC was performed on silica gel 60 F254-coated aluminum sheets (Merck), and spots were detected by a solution of Ce(SO 4 ) 2 ·4H 2 O (1%) and H 3 P(Mo 3 O 10 ) 4 (2%) in sulfuric acid (10%). Flash chromatography was performed on silica gel 60 (0.040-0.063 mm, Fluka) or on Biotage KP-C18-HS or KP-Sil SNAP cartridges using the Isolera One HPFC system (Biotage, Inc.). All chemicals were purchased from Sigma-Aldrich and were used without further purification. Preparative HPLC was performed on a JASCO system equipped with Jasco PU-986 pump and UV-975 detector using an YMC C18 column (5 μm, 20 mm × 250 mm) with a linear gradient of 2-60% acetonitrile/water (0.1% TFA) over 50 min at a flow rate 10 mL/min. NMR spectra were measured on a Bruker Avance III 400 or 500 spectrometer operating at 400.1 MHz ( 1 H) and 100.8 MHz ( 13 C) or at 500.0 MHz ( 1 H) and 125.7 MHz ( 13 C). Chemical shift assignment and confirmation of the structure of compound 26 was achieved by a combination of 1 H, 13 C, and 1 H-13 C HMBC NMR experiments. The ESI mass spectra were recorded using Waters Micromass ZQ mass spectrometer equipped with an ESCi multimode ion source and operated by MassLynx software. The low resolution ESI mass spectra were recorded using a quadrupole orthogonal acceleration time-of-flight tandem mass spectrometer (Q-Tof micro, Waters) and highresolution ESI mass spectra using a hybrid FT mass spectrometer combining a linear ion trap MS and the Orbitrap mass analyzer (LTQ Orbitrap XL, Thermo Fisher Scientific). The conditions were optimized for suitable ionization in the ESI Orbitrap source (sheath gas flow rate 35 au, aux gas flow rate 10 au of nitrogen, source voltage 4.3 kV, capillary voltage 40 V, capillary temperature 275 °C, tube lens voltage 155 V). Purity for each compound was established using HPLC (Jasco Inc.) equipped with a Reprosil 100 C18, 5 μm, 250 mm × 4 0.1% TFA to 100% CH 3 CN, with UV detection at λ = 210 nm. All final compounds tested were confirmed to be of ≥95% purity.
tert-Butyl 4-(2-(tert-Butoxycarbonyl)hex-5-en-1-yl)benzoate (3)-A solution of 4-
(2-carboxyhex-5-en-1-yl)benzoic acid 2 (7.07 g, 28.5 mmol) in anhydrous dichloromethane (120 mL) was cooled to −65 °C, and an excess of isobutylene (23.7 g, 422 mmol) was condensed into the mixture followed by addition of conc H 2 SO 4 (1.6 mL, 28.5 mmol). The reaction vessel was sealed and allowed to reach room temperature. The mixture was stirred overnight, then cooled to −65 °C and poured into saturated aqueous solution of NaHCO 3 . The reaction mixture was extracted with ether (100 mL × 2), and combined organic extracts were dried over MgSO 4 and concentrated in vacuo. The residual oil was chromatographed on silica gel (acetone/hexane, 1:6) to yield 8.49 g of 3 as a syrupy oil (83% yield). 1 were placed in a Schlenk flask and put under an argon atmosphere. After adding methanol (60 mL), the mixture was cooled to 0 °C while stirring. After 15 min, the cooling bath was removed and the mixture was stirred for additional 1 h. The mixture was then filtered through a pad of Celite, yielding the filtrate containing NH 2 OH for the later use. Meanwhile, to a solution of 4 (4.00 g, 10.57 mmol) in THF (100 mL) in a Schlenk flask were added triethylamine (2.2 mL, 15.85 mmol, 1.5 equiv) and ethyl chloroformate (1.6 mL, 15.86 mmol, 1.5 equiv) under an argon atmosphere, and the mixture was stirred at rt for 1 h. A white precipitate formed almost immediately. The filtrate containing NH 2 OH prepared earlier was added, and the mixture was stirred at rt overnight. Volatiles were then removed on a rotavap, and water (100 mL) was added. The mixture was extracted with EtOAc (250 mL × 3). The combined extracts were dried over MgSO 4 and concentrated. The residual material was chromatographed on silica gel (hexanes/EtOAc, 2:3 containing 1% AcOH) to afford 2.63 g of 5 as an orange oil (63% yield, 6.69 mmol). 1 (7)-To a solution of 6 (0.90 g, 2.07 mmol) in dichloromethane (10 mL) were added TFA (5 mL) and i-Pr 3 SiH (428 μL, 2.07 mmol) under an argon atmosphere. The mixture was stirred at rt for 1 h, when disappearance of the starting material was confirmed on TLC. Volatiles were removed on a rotavap, and EtOAc (5 mL) was added to the residual material. A short sonication caused a precipitate formation. After adding hexanes (10 mL) followed by a short sonication, the mixture was filtered to give 0.57 g of 7 as a white solid (86% yield, 1.78 mmol). 1 5 mmol) in DMF (40 mL) was added. The mixture was stirred at rt for 2 h, then water (100 mL) was added and the mixture was extracted with EtOAc (200 mL × 3). The combined organic extracts were washed with water (200 mL × 3), dried over MgSO 4 , and concentrated to give a yellowish solid, which was sonicated in EtOAc (10 mL). After adding hexanes (40 mL), the mixture was sonicated for additional 5 min. The resulting mixture was filtered to afford 4.23 g of 9 as an off-white solid (78% yield, 13.6 mmol). 1 2 mmol, 1.5 equiv) at once at rt under an argon atmosphere. The mixture was stirred at rt for 3 h. Then water (100 mL) was added and the mixture was extracted with EtOAc (120 mL × 3). The combined organic extracts were washed water (100 mL × 3), dried over MgSO 4 , and concentrated. The residue was chromatographed on a silica gel column (hexanes/EtOAc, 1:1) to afford a yellowish oil containing a solid. The mixture was sonicated in EtOAc (5 mL × 5), and then with hexanes (25 mL). The suspension was kept still for 10 min for the precipitate to settle, and the supernatant was separated. The combined supernatants were concentrated to give 881 mg of 11 as a yellowish oil (20% yield, 1.63 mmol). 1 
5-(tert-Butoxy)-4-(4-(tert-butoxycarbonyl)benzyl)-5-oxopentanoic Acid (4)-To
4-(5-(Acetoxyamino)-2-carboxy-5-oxopentyl)benzoic Acid
129.0, 131.2, 131.5, 134.6, 151.5, 163.6, 189.4. HRMS (ESI): [M + Na] + m/z 334.06863
4-(5-(((4-Acetoxybenzyl)oxy)amino)-2-carboxy-5-oxopentyl)-benzoic Acid (12)
-To a solution of 11 (365 mg, 0.67 mmol) in dichloromethane (10 mL) were added TFA (5 mL) and i-Pr 3 SiH (276 μL, 1.35 mmol, 2 equiv) under an argon atmosphere. The mixture was stirred at rt for 1 h, after which time no starting material was detected by TLC. Volatiles were removed on a rotavap, and residual TFA was coevaporated with toluene (5 mL × 3). EtOAc (1 mL) was then added to the residual material and the mixture was sonicated for 5 min, resulting in white precipitate formation. The mixture was centrifuged and the supernatant was removed. The precipitate was sonicated in chloroform (2 mL), filtered, and washed with chloroform (5 mL) to give 165 mg of 12 as a white solid (57% yield, 0.38 mmol). 1 Methyl-2-oxo-1,3-dioxol-4-yl)methoxy)isoindoline-1,3-dione (14) -To a suspension of NaH (287 mg, 7.18 mmol, 1.1 equiv) in DMF (10 mL) was slowly added (over 5 min) a solution of N-hydroxyphthalimide (1.21 g, 7.18 mmol, 1.1 equiv) in DMF (10 mL) at 0 °C under an argon atmosphere. After 5 min of stirring, a solution of 13 (1.00 g, 6.53 mmol) in DMF (5 mL) was added. The mixture was warmed up to rt and then heated at 70 °C for 1 h, during which time the dark-red mixture turned medium beige and the starting material disappeared on TLC. Water (50 mL) was then added to the mixture, and the resulting mixture was extracted with EtOAc (120 mL × 3). The combined organic extracts were washed with water (100 mL × 3) to remove DMF, dried over MgSO 4 , and concentrated. EtOAc (4 mL) was then added to the residual material, and it was sonicated for 10 min. Hexanes (40 mL) were added, and after a short sonication and filtration 1.64 g of 14 was obtained as an off-white solid (92% yield, 5.98 mmol). 1 under an argon atmosphere. A precipitate formed almost immediately, which slowly (5 min) disappeared, leaving a homogeneous mixture and then rapidly a precipitate formed again. The mixture was stirred at rt for 1 h, then it was filtered through a microfilter syringe, and the resulting filtrate containing 15 was used immediately in the subsequent reaction.
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tert-Butyl 4-(2-(tert-Butoxycarbonyl)-5-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)amino)-5-oxopentyl)benzoate (16)-To
a solution of 4 (200 mg, 0.53 mmol) in THF (10 mL) were added triethylamine (89 μL, 0.63 mmol, 1.2 equiv) and ethyl chloroformate (63 μL, 0.63 mmol, 1.2 equiv). The mixture was stirred at rt for 1.5 h, then the filtrate containing 15 prepared above was added at once. The mixture was stirred at rt for 16 h. Water (30 mL) was then added, and the mixture was extracted with EtOAc (100 mL × 3), dried over MgSO 4 , and concentrated. The residual material was chromatographed on a silica gel column (hexanes/EtOAc, 1:1) to afford 104 mg of 16 as a yellowish oil (39% yield, 0.21 mmol). 1 5-methyl-2-oxo-1,3-dioxol-4-yl) under an argon atmosphere. The mixture was stirred at rt for 30 min. Volatiles were removed on a rotavap, and residual TFA was coevaporated with toluene (2 mL × 2). The residual material was sonicated in chloroform (1 mL), filtered, and washed with chloroform (3 mL) to give 35 mg of 17 as a white solid (61% yield, 0.09 mmol). 1 74 (m, 2H), 1.91-2.10 (m, 2H), 2.05 (s, 3H), 2.54-2.63 (m, 1H), 2.74-2.93 (m, 2H) 
4-(2-Carboxy-5-(((
Ethyl 4-(2-(Ethoxycarbonyl)hex-5-en-1-yl)benzoate (18)-To
a solution of 2 (1.00 g, 4.03 mmol) in ethanol (20 mL) was dropwise added SOCl 2 (1.77 mL, 24.4 mmol) at 0 °C over 10 min. The mixture was stirred at rt for 24 h. Volatiles were then removed on a rotavap, and the residual material was chromatographed on a silica gel column (hexanes/ EtOAc, 6:1) to afford 1.12 g of 18 as a yellow oil (91% yield, 3.68 mmol). 1 Butoxy)-4-(4-(ethoxycarbonyl)benzyl)-5-oxopentanoic Acid (21) -To a solution of 20 (225 mg, 0.68 mmol) in acetonitrile (15 mL) and water (15 mL) was added RuO 2 hydrate (14 mg, 0.10 mmol) followed by addition of NaIO 4 (1.45 g, 6.77 mmol) at 0 °C. The mixture was stirred at 0 °C for 15 min and at rt for 6 h, after which no starting material was seen on TLC. The reaction mixture was then filtered through a pad of Celite and washed with additional acetonitrile. The solvents were then removed on a rotavap, and the residual material was extracted with EtOAc (100 mL × 3). The combined organic extracts were dried over MgSO 4 and concentrated. The residual material was chromatographed on a silica gel column (hexanes/EtOAc, 1:1 containing 1% AcOH) to give 132 mg of 21 as a colorless oil (56% yield, 0.38 mmol). 1 -4-(4-(ethoxycarbonyl)benzyl)-5-oxopentanoic Acid (24)-To a solution  of 18 (1.00 g, 3 .29 mmol) in acetonitrile (50 mL) and water (50 mL) was added RuO 2 hydrate (66 mg, 0.49 mmol), followed by addition of NaIO 4 (7.04 g, 32.85 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 min and at rt for 18 h. The reaction mixture was then filtered through a pad of Celite and washed with additional acetonitrile. The volatile solvents were then removed on a rotavap, and the mixture was extracted with EtOAc (150 mL × 3). The combined organic extracts were dried over MgSO 4 and concentrated. The residual material was chromatographed on a silica gel column (hexanes/EtOAc, 1:1 containing 1% AcOH) to give 579 mg of 24 as a colorless oil (55%, 1.80 mmol). 1 Isopropoxycarbonyl)oxy) 4-(2-((2-(Trimethylsilyl)ethoxy) 121.8, 127.1, 129.1, 130.2, 130.4, 133.0, 145.2, 150.9, 153.4, 164.8, 169.5, 170.0 (isopropoxycarbonyl)-oxy) methoxy)carbonyl)benzyl)-5-oxopentanoic Acid (30)-To a solution of 29 (646 mg, 1.00 mmol) in dichloromethane (5 mL) was added TFA (1.5 mL) at 0 °C under an argon atmosphere. The mixture was stirred at 0 °C for 15 min and at rt for 4 h. Volatiles were removed on a rotavap, and the residual TFA was removed by coevaporating with toluene. The residual material was purified on HPLC and lyophilized to give 267 mg of 30 as a white fluffy solid (49% yield, 0.49 mmol). 1 
2-(4-(Ethoxycarbonyl)benzyl)hex-5-enoic Acid (19)-To
5-(tert-
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5-(((4-Acetoxybenzyl)oxy)amino)-2-(4-(((
IC 50 Determination of Prodrugs
Inhibition constants of prodrugs were determined using the radioenzymatic assay with 3 H-NAAG (radiolabeled at the terminal glutamate) as we have previously described. 14 Briefly, rhGCPII (30 ng/mL) was preincubated in the presence of inhibitors at varying concentrations, in 20 mM Tris, 150 mM NaCl, pH 8.0, for 15 min at 37 °C in the total volume of 80 μL. The reaction was initiated by the addition of 40 μL of the mixture of 0.31 μM NAAG (Sigma) and 15 nM 3 H-NAAG (50 Ci/mmol in Tris buffer, PerkinElmer) to the total reaction volume of 120 μL. Following 20 min incubation, the reaction was terminated by addition of 120 μL of potassium phosphate (200 mM), EDTA (50 mM), and β-mercaptoethanol (2mM), pH 7.4. The released glutamate was separated by ion-exchange chromatography and quantified by liquid scintillation counting. GraphPad Prism software (GraphPad Software, San Diego, CA, USA) was used for data fitting, and IC 50 values were calculated from the inhibition curves where applicable.
In Vitro Plasma Metabolite Identification Studies
Plasma stability studies were conducted in mouse plasma as previously described. 12 Compound 1 and prodrugs (12, 23 and 30) (10 μM) were spiked in plasma and incubated in an orbital shaker at 37 °C. At zero and 60 min post incubation, 100 μL aliquots of the mixture in triplicate were removed and the reaction quenched by addition of two times the volume of ice-cold acetonitrile spiked with the internal standard (losartan 5 μM). The samples were vortexed for 30 s and centrifuged at 12000g for 10 min. Supernatant (50 μL) was diluted with 50 μL of water and transferred to a 250 μL of polypropylene vial sealed with a Teflon cap. Prodrug disappearence and metabolite identification were analyzed over time using an Agilent 1260 HPLC coupled to a ESI-TOF Agilent 6530 with Agilent Jet Stream Technology (Agilent Technologies, Santa Clara, CA). Samples were separated on a Waters 1.7 μm, C18, 100 mm × 2.1 mm column at a flow rate 0.3 mL/min. The concentration of mobile phase B (0.1% FA in acetonitrile) was gradually increased from 10 to 100% in mobile phase A (0.1% FA in water) over 7 min. The mass spectrometry instrument was operated in a negative or positive (for JV-2946) ion mode with a voltage of +3.00 kV applied to the capillary. The temperature, the flow rate of the nitrogen drying gas, the pressure of the nitrogen nebulizing gas, the temperature, and the flow rate of the sheath gas were set at 325 °C, 10 L/min, 40 psi, 390 °C, and 11/min, respectively.
Plasma Pharmacokinetic Studies in Mice
All pharmacokinetic studies in mice were conducted according to protocols approved by the Animal Care and Use Committee at Johns Hopkins University (Baltimore, MD). Briefly, male CD 1 mice between 25 and 30 g were obtained from Harlan Laboratories (Indianapolis, Indiana) and maintained on a 12 h light-dark cycle with ad libitum access to food and water. Compound 1 and its prodrugs were administered to male mice as a single (po) dose of 10 mg/kg equivalent. Dosing solutions were prepared on the day of the experiment in 50 mM HEPES buffered saline and pH adjusted to 7.4. The mice were sacrificed by pentobarbital injection at 30 min post drug administration, and blood collected via cardiac puncture was placed into iced heparin coated BD microtainers. Blood samples were spun at 200g for 15 min, and plasma was removed and stored at −80 °C until LC-MS analysis as previously described. 10 Briefly, chromatographic analysis was performed using an Accela ultra highperformance system consisting of an analytical pump an autosampler coupled with TSQ Vantage mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA). Separation of the analyte was achieved using Agilent Eclipse Plus column (100 mm × 2.1 mm i.d.) packed with a 1.8 μm C18 stationary phase. The mobile phase used was composed of 0.1% formic acid in acetonitrile and 0.1% formic acid in H 2 O with gradient elution, starting with 5% (organic) and linearly increasing to 99% up to 2.5 min, maintaining at 99% (2.5-3.5 min), and reequlibrating to5% by 4. 
Chronic Constrictive Injury Model of Neuropathic Pain
All experimental protocols were approved by the Institutional Animal Care and Use Committee at Johns Hopkins University (Baltimore, MD) and adhered to all of the applicable institutional and governmental guidelines for the humane treatment of laboratory animals. Male Sprague-Dawley rats (200-250 g; n = 10-15 per group) were subjected to peripheral neuropathy injury by constriction of the sciatic nerve performed according to methods described previously. 10, 16, 21 In brief, the common sciatic nerve was exposed and four ligatures (4.0 chromic gut) tied loosely around it with 1 mm spacing. Wound clips were used to close wounds, and animals were returned to home cages for recovery. Hyperalgesia testing was initiated 10 days postsurgery. Pain sensitivity was assessed by determining withdrawal latencies in response to a constant thermal stimulus directed to the plantar surface of the hind paw using a Basile Plantar apparatus (Ugo Basile, Vaarese, Italy) according to the method described by Hargreaves et al. 22 Apparatus was calibrated so that normal rats respond to the stimulus within 15 s of application. Withdrawal latency (i.e., the time taken for the rat to withdraw its paw from the heat source) was measured to the nearest 0.1 s. The "difference in score" was calculated by subtracting the average latency of the paw on the nonligated versus ligated side. Each animal was tested during two experimental sessions per week, with 3 days allowed to elapse between test sessions. Test agents, prodrug 12 (3 mg/kg equivalent of 1), or gabapentin (50 mg/kg and 100 mg/kg po) as a positive control were dosed daily throughout the study via oral gavage and 1 h before testing on experimental days. Statistical analysis with students t-test was used to determine differences between control and treatment group.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Structures, IC 50 , and plasma concentrations of compound 1 following oral administration of prodrugs in mice. All prodrug except 17 were >10-fold less potent versus 1 in inhibiting GCP II activity. Six prodrugs, 7, 12, 17, 23, 25, and 30, given po to mice at a dose equivalent of 10 mg/kg of compound 1, and plasma levels of 1 were measured 30 min after administration. Compound 12 showed the highest improvement, delivering concentrations of 1 at greater than 5-fold in plasma vs 1. Data expressed as mean ± SEM, (n = 3). Compound 12 did not affect the response latency to the thermal stimulus applied to the sham-operated side.
